A Pancreatic Cancer Pill for $480,000 a Year: What Happens When Drug Makers Price Out the Sick

Here's what desperation looks like in the American healthcare system: a pancreatic cancer patient facing a choice between a drug that might save their life and financial ruin.

That's the reality the New York Times reported with Rasonque, a new pancreatic cancer treatment from Revolution Medicines priced at $480,000 per year. For context: that's roughly what a full-time worker at median wage earns in a decade. It's more than the median home price in most of America. It's not an outlier anymore, it's the new normal.

Why this matters right now. Cancer drug prices have inflated 50% faster than general inflation over the past 20 years. Patients are rationing doses. Families are going bankrupt. Insurance companies are denying coverage. And the people who make these drugs aren't apologizing, they're calling it the cost of innovation.

Here's what they don't say: the National Institutes of Health funded most of the basic research that led to these drugs. Taxpayers paid for the science. Drug makers are just collecting the profit.

The system that got us here. Drug companies in America can set prices however they want. There's no negotiation. There's no cap. Medicare, which covers 45 million people, is legally banned from negotiating drug prices directly. That's not policy. That's corporate protection masquerading as law.

The result is predictable: other wealthy countries pay a fraction of what Americans do for the same pill. A drug that costs $10,000 in Germany might cost $50,000 here. Not because it's better. Not because it's scarcer. Because we let them.

And when you're dying, you pay.

What needs to change. The Common Good Party believes healthcare is a shared national investment, not a luxury good for the wealthy. That means drug prices need to be honest, transparent, and actually affordable. It means Medicare should negotiate like every other large buyer on Earth. It means patents should reward innovation without pricing out the sick.

A $480,000 pill isn't progress. It's a system that works for shareholders and breaks for everyone else.